DGAP-News: PAION AG: MANAGEMENT BOARD CHANGE

DGAP-News: PAION AG: MANAGEMENT BOARD CHANGE

ID: 33858

(firmenpresse) - DGAP-News: PAION AG / Key word(s): Change of Personnel
PAION AG: MANAGEMENT BOARD CHANGE

21.04.2011 / 08:30

---------------------------------------------------------------------

PAION AG: MANAGEMENT BOARD CHANGE

Aachen (Germany), 21 April 2011 - The biopharmaceutical company PAION AG
(ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today
announces that Dr Gavin Kilpatrick has stepped down from his position as a
member of the Management Board and will be leaving the company on 30 April
2011. In his role as Chief Scientific Officer, Dr Kilpatrick was
responsible for production, pre-clinical development, drug discovery,
project management and intellectual property. Dr Wolfgang Söhngen, PAION's
CEO, and Dr Mariola Söhngen, PAION's CMO, will take over these
responsibilities in the future.

'On behalf of both the Supervisory Board and the Management Board, I would
like to thank Dr Kilpatrick for his major contributions to PAION and
previously CeNeS, with particular thanks for his key role in the
development of Remimazolam.' commented Dr Wolfgang Söhngen. 'I hope that
he will bring through more new rough diamonds in the future. We wish him
all the very best for the future.'

'It has been a pleasure to participate in PAION's development over the last
years,' commented Dr Gavin Kilpatrick. 'I personally would like to
concentrate in the future on earlier stage development programs. PAION has
some excellent compounds in clinical development and I wish all my
colleagues every success in taking these and the company forward.'

###

About PAION
PAION is a biopharmaceutical company headquartered in Aachen, Germany and
has a second site in Cambridge, UK. The company is specialized in
developing and commercialising innovative drugs for the hospital-based
treatment in indications for which there is a substantial unmet medical




need. PAION has a 'Search&Develop' business model, which is based on its
core expertise in drug development. Where appropriate, particularly during
the late stages of the clinical development, PAION seeks to collaborate
with experienced partners.

Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner(at)paion.com
www.paion.com

Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.


End of Corporate News

---------------------------------------------------------------------

21.04.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP'sDistribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Deutschland
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info(at)paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart


End of News DGAP News-Service
---------------------------------------------------------------------
120853 21.04.2011

Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  DGAP-News: Vtion Wireless Technology AG: Strong financial figures 2010, new products in 2011 DGAP-News: HELMA Eigenheimbau AG publishes 2010 annual report
Bereitgestellt von Benutzer: EquityStory
Datum: 21.04.2011 - 08:30 Uhr
Sprache: Deutsch
News-ID 33858
Anzahl Zeichen: 0

contact information:

Kategorie:

Business News



Diese Pressemitteilung wurde bisher 233 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"DGAP-News: PAION AG: MANAGEMENT BOARD CHANGE"
steht unter der journalistisch-redaktionellen Verantwortung von

PAION AG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von PAION AG



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z